DIA Biosimilars 2013

Geron

Geron discontinues GRN100, cuts 43 workers

Wednesday, December 5, 2012 11:08 AM

Geron, a Menlo Park, Calif.-based biopharmaceutical company developing first-in-class therapies for cancer, has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres.

More... »

Cenduit: Now with Patient Reminders

Geron focuses on cancer programs, discontinuing stem cell programs

Tuesday, November 15, 2011 11:51 AM

Geron has reported that the company will focus on its first-in-class oncology programs, effective immediately. As a consequence, the company will discontinue further development of its stem cell programs and is seeking partners for these novel assets.

More... »

CRF Health – eCOA Forum

California state funding advances clinical trials

Thursday, May 5, 2011 01:00 PM

The California Institute for Regenerative Medicine (CIRM) has been awarded taxpayer funding for the first time to study an experimental stem cell treatment on humans, according to The San Diego Union-Tribune.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.